Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hubert H Fernandez

Showing results (21-30 of 260) with videos related to

Pageof 26
Sort By:
Drugs & Aging|July 31, 2008
Pathophysiology and treatment of psychosis in Parkinson's disease: a reviewLaura B Zahodne, Hubert H Fernandez
Expert Opinion on Investigational Drugs|March 22, 2006
Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugsKelvin L Chou, Hubert H Fernandez
The Neurologist|June 13, 2003
Classification and treatment of tardive syndromesHubert H Fernandez, Joseph H Friedman
Archives of Neurology|December 10, 2002
18F-Dopa vs dopamine transporter ligands in positron emission tomographic and single-photon emission computed tomographic scans for Parkinson diseaseHubert H Fernandez, Joseph H Friedman
Journal of the Neurological Sciences|January 21, 2017
Dopamine agonist withdrawal syndrome: A comprehensive reviewXin Xin Yu, Hubert H Fernandez
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|April 16, 2013
Sustained benefit of painful legs moving toes syndrome with botulinum toxin type ARamon L Rodriguez, Hubert H Fernandez
Current Psychiatry Reports|September 16, 2016
Current Understanding of Psychosis in Parkinson's DiseaseOluwadamilola O Ojo, Hubert H Fernandez
Drugs & Aging|August 19, 2007
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitorsJack J Chen, Hubert H Fernandez
Pharmacotherapy|November 29, 2007
Monoamine oxidase-B inhibition in the treatment of Parkinson's diseaseHubert H Fernandez, Jack J Chen
Clinical Neuropharmacology|June 5, 2007
Monamine oxidase inhibitors: current and emerging agents for Parkinson diseaseHubert H Fernandez, Jack J Chen
Pageof 26

Showing results (21-30 of 260) with videos related to

Sort By:
Pageof 26
Drugs & Aging|July 31, 2008
Pathophysiology and treatment of psychosis in Parkinson's disease: a reviewLaura B Zahodne, Hubert H Fernandez
Expert Opinion on Investigational Drugs|March 22, 2006
Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugsKelvin L Chou, Hubert H Fernandez
The Neurologist|June 13, 2003
Classification and treatment of tardive syndromesHubert H Fernandez, Joseph H Friedman
Archives of Neurology|December 10, 2002
18F-Dopa vs dopamine transporter ligands in positron emission tomographic and single-photon emission computed tomographic scans for Parkinson diseaseHubert H Fernandez, Joseph H Friedman
Journal of the Neurological Sciences|January 21, 2017
Dopamine agonist withdrawal syndrome: A comprehensive reviewXin Xin Yu, Hubert H Fernandez
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|April 16, 2013
Sustained benefit of painful legs moving toes syndrome with botulinum toxin type ARamon L Rodriguez, Hubert H Fernandez
Current Psychiatry Reports|September 16, 2016
Current Understanding of Psychosis in Parkinson's DiseaseOluwadamilola O Ojo, Hubert H Fernandez
Drugs & Aging|August 19, 2007
Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitorsJack J Chen, Hubert H Fernandez
Pharmacotherapy|November 29, 2007
Monoamine oxidase-B inhibition in the treatment of Parkinson's diseaseHubert H Fernandez, Jack J Chen
Clinical Neuropharmacology|June 5, 2007
Monamine oxidase inhibitors: current and emerging agents for Parkinson diseaseHubert H Fernandez, Jack J Chen
Pageof 26